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Background: Single arm phase 1 and 2 studies on Crizotinib in ALK-positive patients so far have shown rapid and
durable responses. Spontaneous pneumothoraces as a result of response to anti-cancer therapy are rare in
oncology but have been documented in a number of tumour types including lung cancer. This includes cytotoxic
chemotherapy as well as molecular targeted agents such as gefitinib and Bevacizumab. These often require chest
drain insertion or surgical intervention with associated morbidity and mortality. They have also been associated
with response to treatment. This is the first report we are aware of documenting pneumothorax as response to
crizotinib therapy.
Case presentation: A 48-year-old Caucasian male presented with a Stage IV, TTF1 positive, EGFR wild-type
adenocarcinoma of the lung. He received first line chemotherapy with three cycles of cisplatin-pemetrexed
chemotherapy with a differential response, and then second-line erlotinib for two months before further
radiological evidence of disease progression. Further analysis of his diagnostic specimen identified an ALK
rearrangement by fluorescence in situ hybridization (FISH). He was commenced on crizotinib therapy 250 mg orally
twice daily. At his 4-week assessment he had a chest radiograph that identified a large left-sided pneumothorax
with disease response evident on the right. Chest CT confirmed a 50% left-sided pneumothorax on a background
of overall disease response. A chest tube was inserted with complete resolution of the pneumothorax that did not
recur following its removal.
Conclusion: Our case demonstrates this potential complication of crizotinib therapy and we therefore recommend
that pneumothorax be considered in patients on crizotinib presenting with high lung metastatic burden and with
worsening dyspnoea.
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ALK rearranged lung adenocarcinomaBackground
Crizotinib is approved for ALK rearranged relapsed non-
small cell lung cancer with most patients treated in the
initial expanded cohort phase 1b study acquiring durable
responses. The overall response rate was 57% (CI 46-68)
and the disease-control rate was 87% [1]. A retrospective
study on the same population by Shaw et al. suggested* Correspondence: everlastingaze@gmail.com
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reproduction in any medium, provided the orthat overall survival for patients with advanced ALK-
positive NSCLC was significantly longer in patients given
Crizotinib second- or third-line compared to Crizotinib-na
ïve patients, whose prognosis was very similar to the gen-
eral NSCLC population. This evidence indicates Crizotinib
might prolong overall survival in ALK-positive NSCLC
patients [2]. Regarding the timing of responses, in both the
phase I and phase II trials, the majority were achieved
within 8 weeks of treatment initiation. The duration of
response was 48.1 and 41.9 weeks respectively indicating a
very rapid and prolonged response. Treatment wasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Baseline staging CT scan. CT scan of the chest prior to
commencing treatment with crizotinib exhibiting extensive
metastatic lung disease, mediastinal lymphadenopathy and a
partially collapsed left lung.
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and visual disorders (Grade 1) being the commonest [3,4].
Case presentation
A 48-year-old Caucasian male ex smoker (10 pack-year
tobacco exposure) presented in 2011 with cough and back
pain. Computerized tomography (CT) imaging showed a
lung primary and metastases to both lungs, spine, and left
adrenal. A computerized tomography (CT)-guided biopsy
confirmed TTF1 positive, EGFR wild-type adenocarcin-
oma of the lung. He received three cycles of cisplatin-
pemetrexed chemotherapy with a differential response,
and then second-line erlotinib for two months before fur-
ther radiological evidence of disease progression. Erlotinib
was administered based on the findings of the BR.21 phase
III trial, which demonstrated that erlotinib prolonged
survival in relapsed NSCLC unselected by EGFR genotype
following progression on first- or second-line chemother-
apy compared to placebo (6.7 months vs 4.7 months) [5].
He subsequently received radiotherapy to the spine for
palliation (8Gy, single fraction) followed by radiotherapy
to the mediastinum due to lymphadenopathy (20Gy, 5
fractions). Thereafter, he was referred for further evalu-
ation, where analysis of his diagnostic specimen identified
an ALK rearrangement by fluorescence in situ hybri-
dization (FISH) using the Vysis (Abbott) LSI ALK dual
colour, break apart rearrangement probe (Abbott molecu-
lar, Illinois, Figure 1). Following a baseline staging CT
(Figure 2), which confirmed multiple metastatic sites,
including the lungs and adrenal gland, as well as a chron-
ically collapsed left lung (first seen on CT prior to com-
mencing erlotinib), he was commenced on crizotinib
therapy 250 mg orally twice-daily. At his 2-week assess-
ment, he reported marginal clinical improvement. At his
4-week assessment he complained of worsening dyspnoea,Figure 1 ALK rearrangement as visualised by fluorescence in
situ hybridization (FISH). FISH image of ALK re-arrangement using
the Vysis (Abbott) LSI ALK dual color, break apart rearrangement
probe (Abbott molecular, Illinois).and a chest radiograph identified a large left-sided pneu-
mothorax with disease response evident on the right. Chest
CT confirmed a 50% left-sided pneumothorax on a back-
ground of overall disease response (Figures 3 and 4) with
improvement in mediastinal nodal disease, lung metastases,
and re-canalization of the left main bronchus. The patient
was admitted and chest tube was placed with an under-
water seal. Crizotinib was continued throughout. The left
lung re-expanded fully within 24 hours, with correspondent
symptomatic improvement and remained fully expanded
after removal of the chest tube (Figure 5 and 6) at which
point the patient was discharged. A few weeks later he dete-
riorated clinically due to likely disease progression, active
treatment was discontinued and his care was transferred to
the community palliative care team.Figure 3 Chest CT showing disease response. Staging CT scan
after 4 weeks of crizotinib treatment showing disease response with
improvement in mediastinal nodal disease, lung metastases, and re-
canalization of the left main bronchus.
Figure 4 Chest CT showing disease response and a 50%
left-sided pneumothorax. Staging CT scan following 4 weeks of
treatment showing disease response and a 50% left-sided
pneumothorax on ‘lung windows’.
Figure 6 Chest radiograph following removal of chest drain.
Complete re-expansion of the left lung as seen following removal of
left-sided chest drain for spontaneous pneumothorax secondary to
response to treatment with crizotinib.
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Case reports of remarkable responses to Crizotinib are
emerging. Kim et al., reported a case of a 14-year old girl
with extensive Stage IV (multiple lymph nodes and
lymphangitic lung metastasis), ALK-positive lung adeno-
carcinoma, who was treated with first-line Crizotinib.
An FDG-PET at Day 21 revealed an impressive partial
response across all disease sites. A 9-week CT revealed a
76.3% decrease in tumour bulk and at 64 weeks the pa-
tient remained at confirmed partial response [6].
Spontaneous pneumothoraces as a result of response
to anti-cancer therapy are rare in oncology and typicallyFigure 5 Chest radiograph showing a 50% left-sided
pneumothorax. 50% left-sided pneumothorax as visualised on a
simple chest radiograph following 4 weeks of crizotinib treatment.occur in cases of metastatic osteosarcoma or germ cell
tumours, with case reports in other histologies eg. breast
cancer [7]. Although, spontaneous pneumothoraces have
also been described in primary lung cancer (including
small cell and NSCLC) as initial presentation or as compli-
cation, more commonly, of chest radiotherapy, they have
been very rarely associated with cytotoxic chemotherapy
[8,9]. A retrospective evaluation at a single centre from
Maniwa et al, demonstrated that patients with pneumo-
thorax as a result of treatment for pulmonary malignancy
(primary or metastatic) often require prolonged chest tube
drainage and sometimes surgical drainage, which is associ-
ated with increased peri-operative morbidity and mortality,
highlighting the significance of early diagnosis and prompt
expert management of such cases [10].
Molecular targeted therapies have also been linked with
the development of spontaneous pneumothoraces. Mori
et al., reported a case of bilateral spontaneous pneumo-
thoraces within four weeks of initiation of gefitinib treat-
ment in a patient with multiple bilateral pulmonary
metastases. These were only small and resolved spontan-
eously. Interestingly there was associated treatment re-
sponse in both lungs within the same time period as seen
on CT [11]. Yang et al., reported a case of Bevacizumab-
induced pneumothorax in a patient treated for metastatic
colorectal cancer, including multiple lung metastases. This
required chest tube drainage for 5 days with complete
resolution of the pneumothorax, highlighting the import-
ance of considering this diagnosis in patients with acute
chest discomfort while on Bevacizumab [12]. This is the
first report we are aware of documenting pneumothorax
as response to crizotinib therapy. Proposed mechanisms
include rapid tumour lysis and tissue necrosis in response
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bronchopleural fistula development [8]. In our case, im-
aging did not suggest obvious macroscopic pleural disease
with no pleural nodularity evident, although several of his
lung metastases did abut the pleura.
Conclusion
Our case demonstrates that spontaneous pneumothoraces
are a potential complication of crizotinib therapy and we
therefore recommend that pneumothorax is considered in
patients on crizotinib presenting with high lung metastatic
burden and with worsening dyspnoea.
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